All News

Find press releases issued in the past two years issued by Johnson & Johnson corporate headquarters and our operating companies.

< Prev | | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | .... 39 Next >

Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes

December 12, 2012

Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting

December 11, 2012

FDA Approves Prescribing Information Update for EDURANT® (rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult Patients

December 10, 2012

U.S. FDA Approves Expanded ZYTIGA® Indication For Treatment Of Metastatic Castration-Resistant Prostate Cancer

December 10, 2012

FDA Approves EVARREST™ Fibrin Sealant Patch

December 07, 2012

Janssen Submits Applications Requesting Approval Of STELARA® In U.S. And Europe For Treatment Of Active Psoriatic Arthritis

December 06, 2012

< Prev | | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | .... 39 Next >

Employees

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.